The phase l study of Youngene's leading candidate YG1699 has been completed in the United States in February 2020.Clinical bridging study has been carried out in China and is expected to be completed in early 2022.
Lexicon Preparing to Resubmit Sotag...
Positive Results of a YG1699 Phase ...
Does SGLT1 Inhibition Add to the Be...